ExoRNA Bio was established in September 2021 by Professor Zhang Chenyu and Dr. Meng Xia. It is headquartered in Shenzhen and has subsidiaries in Nanjing and Shanghai.
ExoRNA Bio focuses on drug development for diseases with no cure and unmet clinical needs, especially for diseases of the central nervous system. Its vision is to build a world-leading platform-based innovative nucleic acid drug company.
ExoRNA Biotech has the world-widely unique in-vivo self-assembled exosome nucleic acid drug delivery platform, which has special advantages including multi-organ targeting, breaking-through of the blood-brain barrier, high safety and low cost, and which can solve the current delivery problems of RNA drugs in one stop.